Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2007

Open Access 01-12-2007 | Primary research

Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation

Authors: Khaldoun Al-Romaih, Gino R Somers, Jane Bayani, Simon Hughes, Mona Prasad, Jean-Claude Cutz, Hui Xue, Maria Zielenska, Yuzhuo Wang, Jeremy A Squire

Published in: Cancer Cell International | Issue 1/2007

Login to get access

Abstract

Background

Methylation-mediated silencing of genes is one epigenetic mechanism implicated in cancer. Studies regarding the role of modulation of gene expression utilizing inhibitors of DNA methylation, such as decitabine, in osteosarcoma (OS) have been limited. A biological understanding of the overall effects of decitabine in OS is important because this particular agent is currently undergoing clinical trials. The objective of this study was to measure the response of the OS cell line, U2OS, to decitabine treatment both in vitro and in vivo.

Results

Microarray expression profiling was used to distinguish decitabine-dependent changes in gene expression in U2OS cells, and to identify responsive loci with demethylated CpG promoter regions. U2OS xenografts were established under the sub-renal capsule of immune-deficient mice to study the effect of decitabine in vivo on tumor growth and differentiation. Reduced nuclear methylation levels could be detected in xenografts derived from treated mice by immunohistochemistry utilizing a 5-methylcytidine antibody. Decitabine treatment reduced tumor xenograft size significantly (p < 0.05). Histological analysis of treated U2OS xenograft sections revealed a lower mitotic activity (p < 0.0001), increased bone matrix production (p < 0.0001), and a higher number of apoptotic cells (p = 0.0329). Microarray expression profiling of U2OS cultured cells showed that decitabine treatment caused a significant induction (p < 0.0025) in the expression of 88 genes. Thirteen had a ≥2-fold change, 11 of which had CpG-island-associated promoters. Interestingly, 6 of these 11 were pro-apoptotic genes and decitabine resulted in a significant induction of cell death in U2OS cells in vitro (p < 0.05). The 6 pro-apoptotic genes (GADD45A, HSPA9B, PAWR, PDCD5, NFKBIA, and TNFAIP3) were also induced to ≥2-fold in vivo. Quantitative methylation pyrosequencing confirmed that the tested pro-apoptotic genes had CpG-island DNA demethylationas a result of U2OS decitabine treatment both in vitro and in xenografts

Conclusion

These data provide new insights regarding the use of epigenetic modifiers in OS, and have important implications for therapeutic trials involving demethylation drugs. Collectively, these data have provided biological evidence that one mode of action of decitabine may be the induction of apoptosis utilizing promoter-CpG demethylation of specific effectors in cell death pathways in OS.
Appendix
Available only for authorised users
Literature
1.
Morgan HD, Santos F, Green K, Dean W, Reik W: Epigenetic reprogramming in mammals. Hum Mol Genet. 2005, 14 Spec No 1: R47-58. 10.1093/hmg/ddi114.CrossRefPubMed
2.
Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, Morales C, Moreno V, Esteller M, Capella G, Ribas M, Peinado MA: Chromosomal Instability Correlates with Genome-wide DNA Demethylation in Human Primary Colorectal Cancers. Cancer Res. 2006, 66 (17): 8462-9468. 10.1158/0008-5472.CAN-06-0293.CrossRefPubMed
3.
Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003, 300 (5618): 455-10.1126/science.1083557.CrossRefPubMed
4.
Botuyan MV, Lee J, Ward IM, Kim JE, Thompson JR, Chen J, Mer G: Structural Basis for the Methylation State-Specific Recognition of Histone H4-K20 by 53BP1 and Crb2 in DNA Repair. Cell. 2006, 127 (7): 1361-1373. 10.1016/j.cell.2006.10.043.PubMedCentralCrossRefPubMed
5.
Karagiannis TC, El-Osta A: Chromatin modifications and DNA double-strand breaks: the current state of play. Leukemia. 2006
6.
Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004, 429 (6990): 457-463. 10.1038/nature02625.CrossRefPubMed
7.
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007, 109 (1): 52-57. 10.1182/blood-2006-05-021162.CrossRefPubMed
8.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, Saba H: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006, 106 (8): 1794-1803. 10.1002/cncr.21792.CrossRefPubMed
9.
Ryhanen S, Pirskanen A, Jaaskelainen T, Maenpaa PH: State of methylation of the human osteocalcin gene in bone-derived and other types of cells. J Cell Biochem. 1997, 66 (3): 404-412. 10.1002/(SICI)1097-4644(19970901)66:3<404::AID-JCB12>3.0.CO;2-E.CrossRefPubMed
10.
Locklin RM, Oreffo RO, Triffitt JT: Modulation of osteogenic differentiation in human skeletal cells in Vitro by 5-azacytidine. Cell Biol Int. 1998, 22 (3): 207-215. 10.1006/cbir.1998.0240.CrossRefPubMed
11.
Villagra A, Gutierrez J, Paredes R, Sierra J, Puchi M, Imschenetzky M, Wijnen Av A, Lian J, Stein G, Stein J, Montecino M: Reduced CpG methylation is associated with transcriptional activation of the bone-specific rat osteocalcin gene in osteoblasts. J Cell Biochem. 2002, 85 (1): 112-122. 10.1002/jcb.10113.CrossRefPubMed
12.
Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR: Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet. 2003, 12 (5): 535-549. 10.1093/hmg/ddg034.CrossRefPubMed
13.
Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD, Gazdar AF: Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002, 21 (27): 4345-4349. 10.1038/sj.onc.1205446.CrossRefPubMed
14.
Bogden AE, Haskell PM, LePage DJ, Kelton DE, Cobb WR, Esber HJ: Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol. 1979, 47 (4): 281-293.PubMed
15.
Ian F Tannock RPH: The Basic Science of Oncology. Third Edition. 2004, Toronto, Canada , McGraw-Hill , Medical Publishing Division., 4th
16.
Dotan ZA, Dotan A, Ramon J, Avivi L: Altered mode of allelic replication accompanied by aneuploidy in peripheral blood lymphocytes of prostate cancer patients. Int J Cancer. 2004, 111 (1): 60-66. 10.1002/ijc.20237.CrossRefPubMed
17.
Dass CR, Ek ET, Contreras KG, Choong PF: A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis. 2006, 23 (7-8): 367-380. 10.1007/s10585-006-9046-6.CrossRefPubMed
18.
Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW: Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 2005, 64 (2): 149-159. 10.1002/pros.20225.CrossRefPubMed
19.
Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ: Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006, 12 (13): 4043-4054. 10.1158/1078-0432.CCR-06-0252.CrossRefPubMed
20.
Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ: Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007, 67 (2): 162-171. 10.1002/pros.20508.CrossRefPubMed
21.
Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T: Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer. 1997, 79 (2): 411-415. 10.1002/(SICI)1097-0142(19970115)79:2<411::AID-CNCR26>3.0.CO;2-2.CrossRefPubMed
22.
Patel SJ, Lynch JW, Johnson T, Carroll RR, Schumacher C, Spanier S, Scarborough M: Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol. 2002, 25 (5): 489-495. 10.1097/00000421-200210000-00014.CrossRefPubMed
23.
Bielack SS, Erttmann R, Looft G, Purfurst C, Delling G, Winkler K, Landbeck G: Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS. Cancer Chemother Pharmacol. 1989, 24 (6): 376-380. 10.1007/BF00257446.CrossRefPubMed
24.
Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992, 10 (1): 5-15.PubMed
25.
Munoz Villa A, Ocete G, Aymerich ML, Maldonado S, Otheo E, Calvo M, Amaya J: [Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children]. Med Clin (Barc). 1996, 107 (5): 161-164.
26.
Fulda S, Debatin KM: 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 2006, 25 (37): 5125-5133.PubMed
27.
Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003, 4 (6): 351-358. 10.1016/S1470-2045(03)01115-X.CrossRefPubMed
28.
Villar-Garea A, Esteller M: DNA demethylating agents and chromatin-remodelling drugs: which, how and why?. Curr Drug Metab. 2003, 4 (1): 11-31. 10.2174/1389200033336757.CrossRefPubMed
29.
Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J: Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet. 2002, 133 (2): 105-111. 10.1016/S0165-4608(01)00575-1.CrossRefPubMed
30.
Lopez-Guerrero JA, Lopez-Gines C, Pellin A, Carda C, Llombart-Bosch A: Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol. 2004, 13 (2): 81-91. 10.1097/00019606-200406000-00004.CrossRefPubMed
31.
Oh JH, Kim HS, Kim HH, Kim WH, Lee SH: Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res. 2006, 442: 216-222. 10.1097/01.blo.0000188063.56091.69.CrossRefPubMed
32.
Lim S, Yang MH, Park JH, Nojima T, Hashimoto H, Unni KK, Park YK: Inactivation of the RASSF1A in osteosarcoma. Oncol Rep. 2003, 10 (4): 897-901.PubMed
33.
Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X, Lu Z: Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 2006, 106 (7): 1602-1609. 10.1002/cncr.21762.CrossRefPubMed
34.
Covey JM, Zaharko DS: Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice. Eur J Cancer Clin Oncol. 1985, 21 (1): 109-117. 10.1016/0277-5379(85)90207-X.CrossRefPubMed
35.
Momparler RL: Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther. 1985, 30 (3): 287-299. 10.1016/0163-7258(85)90053-1.CrossRefPubMed
36.
Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, Rogers C, Sopko NA, Linehan WM, Vasselli JR: The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine. Clin Cancer Res. 2004, 10 (20): 7011-7021. 10.1158/1078-0432.CCR-04-0516.CrossRefPubMed
37.
Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M: Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006, 66 (23): 11187-11193. 10.1158/0008-5472.CAN-06-1274.CrossRefPubMed
38.
Cantor JP, Iliopoulos D, Rao AS, Druck T, Semba S, Han SY, McCorkell KA, Lakshman TV, Collins JE, Wachsberger P, Friedberg JS, Huebner K: Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer. 2007, 120 (1): 24-31. 10.1002/ijc.22073.CrossRefPubMed
39.
Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62 (4): 961-966.PubMed
40.
Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP, Huang TH: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 2003, 63 (9): 2164-2171.PubMed
41.
Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD: Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 2006, 66 (15): 7490-7501. 10.1158/0008-5472.CAN-05-4552.CrossRefPubMed
42.
Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol. 2004, 65 (1): 18-27. 10.1124/mol.65.1.18.CrossRefPubMed
43.
Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002, 21 (35): 5496-5503. 10.1038/sj.onc.1205602.CrossRefPubMed
44.
Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I: Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia. 2005, 19 (1): 103-111.PubMed
45.
Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, Doderlein G, Maltry N, Wu W, Lyko F, Niehrs C: Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature. 2007, 445 (7128): 671-675. 10.1038/nature05515.CrossRefPubMed
46.
Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca LM, Crino L, Peschle C, De Maria R: Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res. 2005, 65 (24): 11469-11477. 10.1158/0008-5472.CAN-05-1724.CrossRefPubMed
47.
Xu J, Zhou JY, Tainsky MA, Wu GS: Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 2007, 67 (3): 1203-1211. 10.1158/0008-5472.CAN-06-2310.CrossRefPubMed
48.
Larsen F, Gundersen G, Lopez R, Prydz H: CpG islands as gene markers in the human genome. Genomics. 1992, 13 (4): 1095-1107. 10.1016/0888-7543(92)90024-M.CrossRefPubMed
49.
Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007, 39 (4): 457-466. 10.1038/ng1990.CrossRefPubMed
50.
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000, 24 (2): 132-138. 10.1038/72785.CrossRefPubMed
51.
Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, Otterson GA: Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene. 2001, 20 (53): 7787-7796. 10.1038/sj.onc.1204970.CrossRefPubMed
52.
Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62 (22): 6456-6461.PubMed
53.
Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH: Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res. 2003, 27 (11): 999-1007. 10.1016/S0145-2126(03)00068-7.CrossRefPubMed
54.
Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA: Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer. 2001, 94 (5): 645-651. 10.1002/ijc.1519.CrossRefPubMed
55.
Yan T, Wergedal J, Zhou Y, Mohan S, Baylink DJ, Strong DD: Inhibition of human osteoblast marker gene expression by retinoids is mediated in part by insulin-like growth factor binding protein-6. Growth Horm IGF Res. 2001, 11 (6): 368-377. 10.1054/ghir.2001.0249.CrossRefPubMed
56.
Gallicchio MA, van Sinderen M, Bach LA: Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res. 2003, 35 (11-12): 822-827.PubMed
57.
Liao B, Hu Y, Herrick DJ, Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005, 280 (18): 18517-18524. 10.1074/jbc.M500270200.CrossRefPubMed
58.
Affymetrix: NetAffx. (http://​wwwaffymetrixcom​).
59.
UCSC: Genome Browser Data Base. (http://​genomeucscedu/​).
60.
NCBI: NCBI data base. (http://​wwwncbinlmnihgov​/​geo/​).
61.
Takai D, Jones PA: The CpG island searcher: a new WWW resource. In Silico Biol. 2003, 3 (3): 235-240.PubMed
62.
Rubinstein R, Simon I: MILANO--custom annotation of microarray results using automatic literature searches. BMC Bioinformatics. 2005, 6: 12-10.1186/1471-2105-6-12.PubMedCentralCrossRefPubMed
63.
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4 (5): P3-10.1186/gb-2003-4-5-p3.CrossRefPubMed
64.
Kubota T, Sutcliffe JS, Aradhya S, Gillessen-Kaesbach G, Christian SL, Horsthemke B, Beaudet AL, Ledbetter DH: Validation studies of SNRPN methylation as a diagnostic test for Prader-Willi syndrome. Am J Med Genet. 1996, 66 (1): 77-80. 10.1002/(SICI)1096-8628(19961202)66:1<77::AID-AJMG18>3.0.CO;2-N.CrossRefPubMed
65.
Horsthemke B, Buiting K: Imprinting defects on human chromosome 15. Cytogenet Genome Res. 2006, 113 (1-4): 292-299. 10.1159/000090844.CrossRefPubMed
Metadata
Title
Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation
Authors
Khaldoun Al-Romaih
Gino R Somers
Jane Bayani
Simon Hughes
Mona Prasad
Jean-Claude Cutz
Hui Xue
Maria Zielenska
Yuzhuo Wang
Jeremy A Squire
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2007
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-7-14

Other articles of this Issue 1/2007

Cancer Cell International 1/2007 Go to the issue

Primary research

Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells

Primary research

In vitro characterization and inhibition of the CXCR4/CXCL12 chemokine axis in human uveal melanoma cell lines

Primary research

Selective cytotoxicity of Pancratistatin-related natural Amaryllidaceae alkaloids: evaluation of the activity of two new compounds

Primary research

Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancer

Review

Role of stem cells in cancer therapy and cancer stem cells: a review

Primary research

Cathepsin L increases invasion and migration of B16 melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits